ArcticZymes Technologies ASA (LTS:0DRV) Growth Rank: 6 (As of Sep. 21, 2026) — 25% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0DRV ArcticZymes Technologies ASA LTS:0DRV
72 GF Score
Price kr21.20
GF Value kr27.55
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is ArcticZymes Technologies ASA Growth Rank?

ArcticZymes Technologies ASA LTS:0DRV 72 Growth Rank is 6 as of Sep. 21, 2026, which is 25% below its 10-year median of 8.00. GuruFocus rates LTS:0DRV with a GF Score™ of 72/100 and a GF Value™ of kr27.55 (Modestly Undervalued). The stock has 1 warning sign investors should review.

ArcticZymes Technologies ASA has the Growth Rank of 6.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

ArcticZymes Technologies ASA Growth Rank Related Terms

LTS:0DRV vs VRTX, REGN, MRNA: Growth Rank Comparison

For the Biotechnology subindustry, ArcticZymes Technologies ASA's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ArcticZymes Technologies ASA Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ArcticZymes Technologies ASA's Growth Rank distribution charts can be found below:

* The bar in red indicates where ArcticZymes Technologies ASA's Growth Rank falls into.


LTS:0DRV
72GF Score
ArcticZymes Technologies ASA LTS:0DRV
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 6 mean?
ArcticZymes Technologies ASA (LTS:0DRV) has a Growth Rank of 6 as of Sep. 21, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on ArcticZymes Technologies ASA and its competitors. This is 25% below median its historical median of 8.00. Over the past decade, ArcticZymes Technologies ASA's Growth Rank has ranged from 3.00 to 10.00.
Is ArcticZymes Technologies ASA's Growth Rank too high?
ArcticZymes Technologies ASA's current Growth Rank of 6 is 25% below median its 10-year median of 8.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 10.00. Overall, ArcticZymes Technologies ASA has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ArcticZymes Technologies ASA's Growth Rank compare to VRTX and REGN?
ArcticZymes Technologies ASA's Growth Rank of 6 can be compared against companies in the Biotechnology industry. Historically, ArcticZymes Technologies ASA's own Growth Rank has ranged from 3.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on ArcticZymes Technologies ASA and its competitors. ArcticZymes Technologies ASA's current Growth Rank is 6, which is 25% below median its own 10-year median of 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ArcticZymes Technologies ASA stock overvalued right now?
Based on GuruFocus' analysis, ArcticZymes Technologies ASA (LTS:0DRV) is currently considered Modestly Undervalued. The stock's GF Value™ is kr27.55, compared to a current price of kr21.20 — trading 23% below its estimated fair value. The current Growth Rank is 6, which is 25% below median its 10-year median of 8.00. ArcticZymes Technologies ASA's overall GF Score™ is 72/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For ArcticZymes Technologies ASA (LTS:0DRV), the current Growth Rank is 6 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ArcticZymes Technologies ASA (LTS:0DRV) Overvalued in 2026?

Based on GuruFocus' analysis, ArcticZymes Technologies ASA stock appears to be undervalued. The current stock price of kr21.20 is trading 23% below its estimated GF Value™ of kr27.55. GuruFocus considers ArcticZymes Technologies ASA to be Modestly Undervalued.

Key valuation signals for LTS:0DRV:

  • Growth Rank: 6 (25% below median its 10-year median of 8.00)
  • GF Value™: kr27.55 vs. price of kr21.20 (23% below fair value)
  • GF Score™: 72/100 with 1 warning sign

No single metric tells the full story. See the LTS:0DRV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ArcticZymes Technologies ASA Business Description

Other Exchanges BIOTECO:SwedenAZT:Norway
Address Sykehusveien 23, Tromso, NOR, 9294
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Norway, Germany, France, Italy, UK, Other countries in Europe, and Rest of world.
72GF Score

Get the complete analysis for LTS:0DRV

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr21.20
Price
kr27.55
GF Value